BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28742165)

  • 21. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
    Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
    Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
    Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
    Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular features and evolutionary trajectory of ASCL1
    Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z
    Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
    Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
    Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer.
    Wei J; Liu L; Guo Y; Zhang J; Wang X; Dong J; Xing P; Ying J; Yang L; Li J
    Thorac Cancer; 2021 Jan; 12(1):40-47. PubMed ID: 33191657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of intermediate filament nestin in cell growth of small-cell lung cancer.
    Takakuwa O; Maeno K; Kunii E; Ozasa H; Hijikata H; Uemura T; Kasai D; Ohkubo H; Miyazaki M; Oguri T; Niimi A
    Lung Cancer; 2013 Aug; 81(2):174-9. PubMed ID: 23706418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
    Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
    Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.
    Kim JH; Lee SY; Choi JE; Do SK; Lee JH; Hong MJ; Kang HG; Lee WK; Shin KM; Jeong JY; Choi SH; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Thorac Cancer; 2020 Jan; 11(1):19-28. PubMed ID: 31691490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ASCL1 represses a SOX9
    Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
    Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.
    Jiang T; Collins BJ; Jin N; Watkins DN; Brock MV; Matsui W; Nelkin BD; Ball DW
    Cancer Res; 2009 Feb; 69(3):845-54. PubMed ID: 19176379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
    Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
    Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer.
    Chen C; Breslin MB; Lan MS
    Cell Signal; 2018 Jun; 46():83-91. PubMed ID: 29501727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation.
    Chen H; Gesumaria L; Park YK; Oliver TG; Singer DS; Ge K; Schrump DS
    Mol Cancer Res; 2023 Feb; 21(2):91-101. PubMed ID: 36378541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.
    Costanzo F; Martínez Diez M; Santamaría Nuñez G; Díaz-Hernandéz JI; Genes Robles CM; Díez Pérez J; Compe E; Ricci R; Li TK; Coin F; Martínez Leal JF; Garrido-Martin EM; Egly JM
    EMBO Mol Med; 2022 Apr; 14(4):e14841. PubMed ID: 35263037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
    Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
    J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct microRNA Signature and Suppression of ZFP36L1 Define ASCL1-Positive Lung Adenocarcinoma.
    Enokido T; Horie M; Yoshino S; Suzuki HI; Matsuki R; Brunnström H; Micke P; Nagase T; Saito A; Miyashita N
    Mol Cancer Res; 2024 Jan; 22(1):29-40. PubMed ID: 37801008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting SIM2-s decreases glioma cell invasion through mesenchymal--epithelial transition.
    Su Y; Wang J; Zhang X; Shen J; Deng L; Liu Q; Li G
    J Cell Biochem; 2014 Nov; 115(11):1900-7. PubMed ID: 24909296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Ikematsu Y; Tanaka K; Toyokawa G; Ijichi K; Ando N; Yoneshima Y; Iwama E; Inoue H; Tagawa T; Nakanishi Y; Okamoto I
    Lung Cancer; 2020 Aug; 146():97-104. PubMed ID: 32526603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
    Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
    Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.